

Microbix expands pandemic test controls portfolio

Nov. 22, 2021—[Microbix Biosystems](#) has expanded its portfolio of Quality Assessment Products to include controls that support PCR tests for four major variants of concern of SARS-CoV-2.

The company says it has developed and is commercializing IVD quality controls to support workflow accuracy of clinical laboratory PCR tests for the Brazilian (P.1), delta (B.1.617), South African (B.1.351), and U.K. (B.1.1.7) VOCs, in addition to QAPs for the Wuhan strain of the virus. The controls are made using Copan FLOQSwabs and have a room temperature stability of 12 months.

The QAPs are branded as a REDx FLOQ SARS-CoV-2 P.1, B.1.617, B.1.351, and B.1.1.7 Swab Positive Control, respectively, and aim to support clinical laboratory quality management systems covering central lab and point-of-care workflows in the U.S. and Canada.